Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

vabametkib (ABN401)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Abion

Drug class:

c-MET inhibitor

Related drugs:

›

MET exon 14 mutation	Non Small Cell Lung Cancer	MET exon 14 mutation	Non Small Cell Lung Cancer	ABN401 Sensitive: C2 – Inclusion Criteria ABN401 Sensitive : C2	ABN401 Sensitive: C2 – Inclusion Criteria ABN401 Sensitive : C2
MET amplification	Non Small Cell Lung Cancer	MET amplification	Non Small Cell Lung Cancer	ABN401 Sensitive: C2 – Inclusion Criteria ABN401 Sensitive : C2	ABN401 Sensitive: C2 – Inclusion Criteria ABN401 Sensitive : C2
MET amplification + EGFR mutation	Non Small Cell Lung Cancer	MET amplification + EGFR mutation	Non Small Cell Lung Cancer	lazertinib + ABN401 Sensitive: D – Preclinical lazertinib + ABN401 Sensitive : D	lazertinib + ABN401 Sensitive: D – Preclinical lazertinib + ABN401 Sensitive : D